Gilead Sciences, Inc. (Nasdaq: GILD) and Arcus Biosciences, Inc. (NYSE: RCUS) have released promising new data from their collaborative study, ARC-9, during an oral session at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. The Phase 1b/2 study assessed the efficacy of etrumadenant combined with zimberelimab, FOLFOX chemotherapy, and bevacizumab (EZFB) in treating […]
Lupin, an Indian pharmaceutical company, has announced a strategic collaboration with Enzene Biosciences, a subsidiary of Alkem Laboratories, to introduce Cetuximab in India. Cetuximab is the first biosimilar developed for Eli Lilly and Company’s Cetuximab, a monoclonal antibody medication used in the treatment of various types of cancer, including head and neck cancer and metastatic […]
Takeda Pharmaceutical will acquire an exclusive worldwide license, excluding China, of fruquintinib from Hutchmed (China) and its subsidiary Hutchmed to strengthen its oncology portfolio. Under the licensing agreement, the Japanese pharmaceutical company will further develop and market the VEGFR1/2/3 tyrosine kinase inhibitor in all indications and territories outside of mainland China, Hong Kong, and Macau. […]
American biotechnology company Seagen (formerly Seattle Genetics) has received accelerated approval from the US Food and Drug Administration (FDA) for the company’s oral drug Tukysa (tucatinib) in combination with trastuzumab. Tukysa in combination with trastuzumab is indicated for the treatment of adult patients with RASwild-type, HER2-positive unresectable or metastatic colorectal cancer, which has advanced following […]
Array BioPharma has achieved a significant regulatory milestone as its innovative combination therapy for metastatic colorectal cancer (mCRC) has been granted breakthrough therapy designation by the U.S. Food and Drug Administration (FDA). The designation specifically targets the treatment regimen combining encorafenib (BRAFTOVI), binimetinib (MEKTOVI), and cetuximab for mCRC patients with the BRAFV600E mutation, following the […]
Vyriad, a US-based biotech company, has partnered with Germany’s Merck to initiate a Phase 1 clinical trial targeting metastatic colorectal cancer. This trial explores the combined potential of Vyriad’s Voyager-V1 and Merck’s Bavencio (avelumab), offering a new approach to immuno-oncology treatment. Voyager-V1, developed by Vyriad, is an oncolytic virotherapy employing a bullet-shaped, negative-sense RNA virus […]
